Publications
Pubblications
and downloadsGrowth trajectories before and after switching to dolutegravir in children living with HIV in the ODYSSEY trial
Authors: Chan MK, Crichton S, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kityo CM, Ahimbisibwe GM, Variava E, Violari A, Cotton M, Archary M, Cressey TR, Puthanakit T, Bandi S, Bwakura-Dangarembizi M, Bbuye D, Atwine L, Kaudha E, White E, Giaquinto C, Rojo P, Gibb DM, Turkova A, Ford D, and the ODYSSEY Trial Team.
Presented at: International workshop on pediatrics and HIV 2025
Pregnancies among adolescents and young women on dolutegravir vs standard-of-care in the ODYSSEY trial and effects of the dolutegravir neural tube defect safety alert
Authors: Ahimbisibwe G, Wyncoll J, Mngqibisa R, White E, Bwakura-Dangarembizi M, Kekitiinwa AR, Lugemwa A, Kityo CM, Variava E, Liberty A, Kataike H, Ngampiyaskul C, Cotton MF, Riault Y, Archary M, Smit T, Puthanakit T, Shakeshaft C, Nhema R, Bbuye D, Atwine L, Kaudha E, Giaquinto C, Rojo P, Bamford A, Gibb DM, Turkova A, Ford D, Musoke P, and the ODYSSEY Trial Team
Presented at: International workshop on pediatrics and HIV 2025
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial
Authors: Wyncoll J, Archary M, Kamolrattana R, Mujuru HA, Kekitiinwa AR, Violari A, Na-Rajsima S, Lugemwa A, Variava E, Cotton M, Kityo CM, Puthanakit T, Königs C, Behuhuma O, Welch S, Saïdi Y, Marques L, Ahimbisibwe GM, Holden L, Giaquinto C, Rojo P, Gibb DM, Turkova A, White E, Ford D, and the ODYSSEY Trial Team
Presented at: IAS 2025
Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials
Authors: Amuge P, Jackson C, Bwakura-Dangarembizi M, Kityo C, Lugemwa A, Chabala C, Nyathi M, Nduna B, Musoke P, Yawe I, Kaudha E, Musoro G, Ankunda R, Bbuye D, Violar A, Variava E, Archary M, Cotton M, Cressey RT, Ndebele W, Mulenga V, Mwamabazi M, Szubert A, White E, Walker AS, Elyanu JP, Kekitiinwa RA, Bamford A, Rojo R, Crichton S, Gibb D, Turkova A, Musiime V, Ford D on behalf of the CHAPAS-4 trial, ODYSSEY trial and UNIVERSAL teams
Presented at: International Workshop on HIV and Pediatrics 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
Authors: White E, Kityo C, Spyer MJ, Mujuru HA, Nankya I, Kekitiinwa AR, Lugemwa A, Kaudha E, Liberty A, Cassim H, Archary M, Cotton MF, Ahimbisibwe GM, Cressey TR, Ngampiyaskul C, Srirompotong U, Behuhuma O, Saidi Y, Bamford A, Kobbe R, Nastouli E, Rojo P, Giaquinto C, Gibb DM, Ford D, Turkova A; on behalf of the ODYSSEY trial team.
Published in: The Lancet HIV
ODYSSEY 192-week follow-up evidences superior efficacy of DTG for children on first/second-line ART
Authors: Mujuru AH, White E, Kekitiinwa A, Lugemwa A, Kityo C, Musoke P, Cressey RT, Variava E, Violari A, Archery M, Cotton M, Puthanakit T, Rojo P, Turkova A
Presented at: CROI 2024
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial
Authors: Barlow-Mosha L.N., Ahimbisibwe G.M., Chappell E., Amuge P.M., Nanduudu A., Kaudha E., Amukele T., Balamusani D., Kafufu B., Nimwesiga A., Kataike H., Namwanje R., Kasangaki G., Mulindwa A., Muzorah, G.A., Bbuye D., Musiime V., Mujyambere E., Ssenyonga M., Mulima D., Kyambadde R.C., Namusanje J., Isabirye R., Nabalamba M., Nakirya B.M., Kityo C., Kekitiinwa A.R., Giaquinto, C., Copp A., Gibb, D.M., Ford, D., Musoke P., Turkova A
Published in : Journal of the International AIDS Society
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
Authors: Turkova A, White E, Kekitiinwa RA, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe MG, Moloantoa T, Srirompotong U, Mosia RN, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi FM, Klein N, Mujuru AH, Kityo C, Cotton FM, Ferrand AR, Giaquinto C, Rojo P, Violari A, Gibb MD, Ford D, on behalf of the ODYSSEY trial team
Published in : The Lancet Child and Adolescent Health
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
Authors: Amuge P, Lugemwa A, Wynne B, Mujuru AH, Violari A, Kityo MC, Archary M, Variava E, White E, Turner MR, Shakeshaft C, Ali S, Nathoo JK, Atwine L, Liberty A, Bbuye D, Kaudha E, Mngqibisa R, Mosala M, Mumbiro V, Nanduudu A, Ankunda R, Maseko L, Kekitiinwa RA, Giaquinto C, Rojo P, Gibb MD, Turkova A, Ford D on behalf of the ODYSSEY Trial Team
Published in : The Lancet HIV
Voluntary Consent to Research on HIV-infected Children in the CHAPAS-4 and ODYSSEY HIV Clinical Trials
Authors: Makumbi S, Bajunirwe F, Ford D, Turkova A, Lugemwa A, Musiime V, Gibb D, Tamwesigire K.I
Presented at: International Workshop on HIV & Pediatrics 2022

